T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback